Esmo 2015 Highlights.
IMMUNO-ONCOLOGIA
In Evidenza
2020 World Conference of Lung Cancer Singapore
Intervista di approfondimento a cura di Filippo de Marinis Grazie a un contributo non condizionante di
Contributi
Video, Slide, Cartelle Zip
ESMO 2015 - Poster Session Display – 26/09/2015
Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
Intervista a Lucio Crinò
ESMO 2015 - Poster Session Display– 27/09/2015
Lung cancer localised/local regional disease
Intervista a Cesare Gridelli
ESMO 2015 - Poster Session Discussion– 27/09/2015
NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes
Intervista a Federico Cappuzzo
ESMO 2015 - Proffered Paper Session – 28/09/2015
Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
Intervista a Filippo de Marinis
ESMO 2015 - Proffered Paper Session – 28/09/2015
Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
Intervista a Filippo de Marinis
ESMO 2015 - Proffered Paper Session – 28/09/2015
Efficacy and safety of Pembrolizumab (MK-3475) for patients with previously treated advanced NSCLC enrolled in KEYNOTE-001
Intervista a Filippo de Marinis
Diventa socio AIOT, entra e compila il form di registrazione.
